RT Journal Article
SR Electronic
T1 Epidemiology and role of SARS-CoV-2 Linkage in Paediatric Inflammatory Multisystem Syndrome (PIMS): A Canadian Paediatric Surveillance Program National Prospective Study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.05.27.22275613
DO 10.1101/2022.05.27.22275613
A1 Tala El Tal
A1 Marie-Paule Morin
A1 Shaun K. Morris
A1 Daniel S. Farrar
A1 Roberta A Berard
A1 Fatima Kakkar
A1 Charlotte Moore Hepburn
A1 Krista Baerg
A1 Camille Beaufils
A1 Terri-Lyn Bennett
A1 Susanne M Benseler
A1 Guillaume Beaudoin-Bussières
A1 Kevin Chan
A1 Claude Cyr
A1 Nagib Dahdah
A1 Elizabeth J. Donner
A1 Olivier Drouin
A1 Rojiemiahd Edjoc
A1 Maryem Eljaouhari
A1 Joanne E. Embree
A1 Catherine Farrell
A1 Andrés Finzi
A1 Sarah Forgie
A1 Ryan Giroux
A1 Kristopher T. Kang
A1 Melanie King
A1 Melanie Laffin Thibodeau
A1 Bianca Lang
A1 Ronald M. Laxer
A1 Thuy Mai Luu
A1 Brian W. McCrindle
A1 Julia Orkin
A1 Jesse Papenburg
A1 Catherine M. Pound
A1 Victoria E. Price
A1 Jean-Philippe Proulx-Gauthier
A1 Rupeena Purewal
A1 Manish Sadarangani
A1 Marina l. Salvadori
A1 Roseline Thibeault
A1 Karina A. Top
A1 Isabelle Viel-Thériault
A1 Elie Haddad
A1 Rosie Scuccimarri
A1 Rae S. M. Yeung
YR 2022
UL http://medrxiv.org/content/early/2022/05/27/2022.05.27.22275613.abstract
AB Background Paediatric inflammatory multisystem syndrome (PIMS) is a rare but serious condition temporally associated with SARS-CoV-2 infection. Using the Canadian Paediatric Surveillance Program (CPSP), a national surveillance system, we aimed to 1) study the impact of SARS-CoV-2 linkage on clinical and laboratory characteristics, and outcomes in hospitalized children with PIMS across Canada 2) identify risk factors for ICU admission, and 3) establish the minimum national incidence of hospitalizations due to PIMS and compare it to acute COVID-19.Methods Weekly online case reporting was distributed to the CPSP network of more than 2800 pediatricians, from March 2020 to May 2021. Comparisons were made between cases with respect to SARS-CoV-2 linkage. Multivariable modified Poisson regression was used to identify risk factors for ICU admission and Minimum incidence proportions were calculated.Findings In total, 406 PIMS cases were analyzed, of whom 202 (49· 8%) had a positive SARS-CoV-2 linkage, 106 (26· 1%) had a negative linkage, and 98 (24· 1%) had an unknown linkage. The median age was 5· 4 years (IQR 2· 5–9· 8), 60% were male, and 83% had no identified comorbidities. Compared to cases with a negative SARS-CoV-2 linkage, children with a positive SARS-CoV-2 linkage were older (8· 1 years [IQR 4· 2–11· 9] vs. 4· 1 years [IQR 1· 7–7· 7]; p<0· 001), had more cardiac involvement (58· 8% vs. 37· 4%; p<0· 001), gastrointestinal symptoms (88· 6% vs. 63· 2%; p<0· 001), and shock (60· 9% vs. 16· 0%; p<0· 001). At–risk groups for ICU admission include children ≥ 6 years and those with a positive SARS-CoV-2 linkage. No deaths were reported. The minimum incidence of PIMS hospitalizations during the study period was 5· 6 hospitalizations per 100,000 population <18 years.Interpretation While PIMS is rare, almost 1 in 3 hospitalized children required ICU admission and respiratory/hemodynamic support, particularly those ≥ 6 years and with a positive SARS-CoV-2 linkage.Funding Financial support for the CPSP was received from the Public Health Agency of Canada.Competing Interest StatementMarie-Paule Morin has received consulting fees from Sobin and Abbvie and payment for expert testimony from the Canadian Medical Protective Association. Shaun Morris has received honouraria for lectures from GlaxoSmithKline, was a member of ad hoc advisory boards for Pfizer Canada and Sanofi Pasteur, and is an investigator on an investigator led grant from Pfizer. Roberta Berard has received honoraria and participated in advisory boards with SOBI, Roche, Amgen, and AbbVie. Krista Baerg served as Past President of the Community Paediatrics Section of the Canadian Paediatric Society and has received royalties from Brush Education. Kevin Chan is Chair of the Acute Care Committee of the Canadian Paediatric Society and is past-president of the Emergency Medicine Section of the Canadian Paediatric Society. Elizabeth Donner is Chair of the Scientific Research Committee and a director of Epilepsy Canada. She is also a member of Partners Against Mortality in Epilepsy and the advisory boards of Cardiol, Pendopharm and Stoke Therapeutics. Catherine Farrell is Chair of the Scientific Steering Committee for the Canadian Paediatric Surveillance Program, former Chair of the Specialty Committee in Pediatrics of the Royal College of Physicians and Surgeons of Canada, former President of the Canadian Paediatric Society, and member of the Executive as Secretary of the Canadian Critical Care Society. She has received reimbursement for travel expenses from Canadian Paediatric Society and the Royal College of Physicians and Surgeons of Canada. She has also received an honorarium for a presentation at a continuing education conference from the Universite de Sherbrooke. Sarah Forgie is the President of the Association of Medical Microbiology and Infectious Disease Canada and has received consulting fees from Toronto Metropolitan University. Fatima Kakkar has received honoraria for presentations given to the Association des Pediatres du Quebec and receives CMV testing kits from Altona Diagnostics. Ronald Laxer has received honoraria for serving as a consultant to Sobi, Novartis, Sanofi, and Eli Lilly, as chair for data monitoring committees for Eli Lilly and Novartis, and from the Canadian Rheumatology Association. Charlotte Moore Hepburn is the Director of Children's Mental Health of Ontario, and the Director of medical affairs for the Canadian Paediatric Society and the Canadian Paediatric Surveillance Program. Jesse Papenburg has received consultant fees from AbbVie, honouraria from AbbVie, AstraZeneca and Seegene, and he received respiratory virus testing materials from Seegene for his institution. He has participated in ad hoc advisory board meetings for AbbVie and Merck and is a voting member of the National Advisory Committee on Immunization. Rupeena Purewal is a consultant for Verity Pharmaceuticals. Manish Sadarangani is supported via salary awards from the BC Children's Hospital Foundation and the Michael Smith Foundation for Health Research and has been an investigator on projects funded by GlaxoSmithKline, Merck, Moderna, Pfizer, Sanofi-Pasteur, Seqirus, Symvivo and VBI Vaccines. All funds have been paid to his institute, and he has not received any personal payments. Marina Salvadori is an employee of the Public Health Agency of Canada. Rosie Scuccimarri has received honoraria and served on an advisory board and as a consultant with Novartis, honoraria from Canadian Rheumatology Association, is a board member for Rheumatology for All, and her institution receives funding from Bristol Myers Squibb for a patient registry for which she is PO. Elie Haddad has participated in advisory board meetings of CSL-Behring and Takeda, data safety monitoring boards of Rocket Pharmaceutical and Jasper Therapeutics, and has a patent application with the biotech Immugenia and the biotech Immune Biosolutions. All other authors report no declaration of interests.Funding StatementFinancial support for the CPSP was received from the Public Health Agency of Canada. The authors and their institutions did not at any time receive payment or services from a third party for any aspect of the submitted workAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research ethics approval was obtained at Health Canada-PHAC (REB #2020-002P), The Hospital for Sick Children (REB #1000070001), the Centre Hospitalier Universitaire Sainte-Justine (CHUSJ) (IRB #MP-21-2021-2901), and at individual sites as required by local policies. In Quebec, the study was conducted as a multicenter study with clinical data collected by study co-investigators, and serologies from CHUSJ done for research purposes (REB #3195) prior to introduction of clinical testing were also included.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDe-identified data that underlie the results reported in this article (text, tables, figures and appendices) and that abide by the privacy rules of the Canadian Paediatric Surveillance Program and the Public Health Agency of Canada can be made available to investigators whose secondary data analysis study protocol has been approved by an independent research ethics board.